Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katie Vo

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Biorxiv : the Preprint Server for Biology|October 17, 2024
Ethanol drinking sex-dependently alters cortical IL-1β synaptic signaling and cognitive behavior in miceAndrea Liss, Mahum Siddiqi, Dhruba Podder, et al.
Health Communication|June 30, 2025
Key Storytellers of Health Information Among Spanish-Speaking Latino Sexual Minority Men in the U.S.: Identifying Barriers and Facilitators to HIV Prevention and CareJane J Lee, Kathleen Agudelo Paipilla, Patricia Alarcon, et al.
Stroke|December 15, 2010
Early changes of tissue perfusion after tissue plasminogen activator in hyperacute ischemic strokeHongyu An, Andria L Ford, Katie Vo, et al.
JMIR Formative Research|January 27, 2026
Development of a Social Media Campaign to Support HIV Prevention and Care Among Transgender Latina Women: Community-Engaged Mixed Methods Feasibility Pilot StudyJane J Lee, Kathleen Agudelo Paipilla, Joel Aguirre, et al.
Cancer|March 24, 2007
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetanThomas E Witzig, Arturo Molina, Leo I Gordon, et al.
Clinical Lymphoma & Myeloma|November 21, 2007
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphomaGregory A Wiseman, Peter S Conti, Katie Vo, et al.
Clinical Lymphoma|January 8, 2005
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literatureStephen M Ansell, Russell J Schilder, Peter C Pieslor, et al.
Clinical Lymphoma|September 30, 2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphomaLeo I Gordon, Thomas Witzig, Arturo Molina, et al.
JCI Insight|January 20, 2022
Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndromeJulia C Stokes, Rebecca L Bornstein, Katerina James, et al.
Blood|March 13, 2019
Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemiaMelanie E Fields, Kristin P Guilliams, Dustin Ragan, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Biorxiv : the Preprint Server for Biology|October 17, 2024
Ethanol drinking sex-dependently alters cortical IL-1β synaptic signaling and cognitive behavior in miceAndrea Liss, Mahum Siddiqi, Dhruba Podder, et al.
Health Communication|June 30, 2025
Key Storytellers of Health Information Among Spanish-Speaking Latino Sexual Minority Men in the U.S.: Identifying Barriers and Facilitators to HIV Prevention and CareJane J Lee, Kathleen Agudelo Paipilla, Patricia Alarcon, et al.
Stroke|December 15, 2010
Early changes of tissue perfusion after tissue plasminogen activator in hyperacute ischemic strokeHongyu An, Andria L Ford, Katie Vo, et al.
JMIR Formative Research|January 27, 2026
Development of a Social Media Campaign to Support HIV Prevention and Care Among Transgender Latina Women: Community-Engaged Mixed Methods Feasibility Pilot StudyJane J Lee, Kathleen Agudelo Paipilla, Joel Aguirre, et al.
Cancer|March 24, 2007
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetanThomas E Witzig, Arturo Molina, Leo I Gordon, et al.
Clinical Lymphoma & Myeloma|November 21, 2007
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphomaGregory A Wiseman, Peter S Conti, Katie Vo, et al.
Clinical Lymphoma|January 8, 2005
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literatureStephen M Ansell, Russell J Schilder, Peter C Pieslor, et al.
Clinical Lymphoma|September 30, 2004
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphomaLeo I Gordon, Thomas Witzig, Arturo Molina, et al.
JCI Insight|January 20, 2022
Leukocytes mediate disease pathogenesis in the Ndufs4(KO) mouse model of Leigh syndromeJulia C Stokes, Rebecca L Bornstein, Katerina James, et al.
Blood|March 13, 2019
Hydroxyurea reduces cerebral metabolic stress in patients with sickle cell anemiaMelanie E Fields, Kristin P Guilliams, Dustin Ragan, et al.
Pageof 3